MX2017015456A - Compuestos de pirazol y pirrol sustituidos y metodos para su uso por inhibición de iniciación de traducción y tratamiento de enfermedades y trastornos relacionados con ellos. - Google Patents

Compuestos de pirazol y pirrol sustituidos y metodos para su uso por inhibición de iniciación de traducción y tratamiento de enfermedades y trastornos relacionados con ellos.

Info

Publication number
MX2017015456A
MX2017015456A MX2017015456A MX2017015456A MX2017015456A MX 2017015456 A MX2017015456 A MX 2017015456A MX 2017015456 A MX2017015456 A MX 2017015456A MX 2017015456 A MX2017015456 A MX 2017015456A MX 2017015456 A MX2017015456 A MX 2017015456A
Authority
MX
Mexico
Prior art keywords
methods
initiation
inhibition
translation
diseases
Prior art date
Application number
MX2017015456A
Other languages
English (en)
Inventor
Alan B Cooper
Stephane Ciblat
Arshad Siddiqui M
Dery Martin
Constantineau-Forget Lea
Grand-Maitre Chantal
Guo Xiangyu
Srivastava Sanjay
W Shipps Gerald
Bruneau-Latour Nicolas
Linh Ly Vu
Original Assignee
Bantam Pharmaceutical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bantam Pharmaceutical Llc filed Critical Bantam Pharmaceutical Llc
Publication of MX2017015456A publication Critical patent/MX2017015456A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos de pirazol, así como composiciones farmacéuticas y métodos de uso de los mismos. Una modalidad es un compuesto que tiene la estructura (I) y sales farmacéuticamente aceptables y N-óxidos de los mismos, en donde X1, X2, Z1, Z2, el sistema de anillo indicado por "a", R1, A1A, L1B, L1A, L2, Q, L3, R3, A4A, L4B, A4B, L4A, R4, L5 y R5 son como se describen aquí. En ciertas modalidades, los compuestos descritos aquí rompen la interacción elF4E/eiF4G, y pueden usarse para tratar un trastorno hiperproliferativo, una enfermedad o trastorno neurológico, o autismo.
MX2017015456A 2015-06-01 2016-06-01 Compuestos de pirazol y pirrol sustituidos y metodos para su uso por inhibición de iniciación de traducción y tratamiento de enfermedades y trastornos relacionados con ellos. MX2017015456A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562169376P 2015-06-01 2015-06-01
PCT/US2016/035288 WO2016196644A1 (en) 2015-06-01 2016-06-01 Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto

Publications (1)

Publication Number Publication Date
MX2017015456A true MX2017015456A (es) 2018-11-29

Family

ID=56118071

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015456A MX2017015456A (es) 2015-06-01 2016-06-01 Compuestos de pirazol y pirrol sustituidos y metodos para su uso por inhibición de iniciación de traducción y tratamiento de enfermedades y trastornos relacionados con ellos.

Country Status (9)

Country Link
US (2) US10537558B2 (es)
EP (1) EP3303332A1 (es)
JP (1) JP6707630B2 (es)
CN (1) CN108349962A (es)
BR (1) BR112017025851A2 (es)
CA (1) CA3025492A1 (es)
IL (1) IL255898A (es)
MX (1) MX2017015456A (es)
WO (1) WO2016196644A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016196644A1 (en) 2015-06-01 2016-12-08 Bantam Pharmaceutical, Llc Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto
US20200069656A1 (en) * 2016-11-30 2020-03-05 Bantam Pharmaceutical, Llc Methods of Using Substituted Pyrazole and Pyrazole Compounds and for Treatment of Hyperproliferative Diseases
BR112019011044A2 (pt) * 2016-11-30 2019-10-08 Bantam Pharmaceutical Llc compostos pirazol substituídos e métodos de uso no tratamento de doenças hiperproliferativas
BR112020019804A2 (pt) 2018-03-30 2021-01-05 Sumitomo Chemical Company, Limited Composto heterocíclico e composição de controle de peste artrópode contendo o mesmo
CN112770813A (zh) * 2018-06-07 2021-05-07 班塔姆制药有限责任公司 用经取代的吡咯和吡唑化合物治疗癌症及诊断对用经取代的吡咯和吡唑化合物的治疗敏感的癌症的方法
CN110950848B (zh) * 2018-09-27 2024-03-26 徐诺药业 新型氨基吡唑类衍生物的合成与应用
WO2020243582A1 (en) * 2019-05-31 2020-12-03 Bantam Pharmaceutical, Llc Methods for making thiszolylpyrazole carboxylic acids and intermediates therefor
CN114502551B (zh) 2019-11-01 2023-08-22 优迈特株式会社 含氟嘧啶化合物及其制备方法
EP4114529A1 (en) * 2020-03-03 2023-01-11 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342851A (en) * 1992-10-07 1994-08-30 Mcneil-Ppc, Inc. Substituted thiazole derivatives useful as platelet aggregation inhibitors
IT1301968B1 (it) * 1998-07-30 2000-07-20 Zambon Spa Derivati di eritromicina ad attivita' antibiotica
TR200302047T4 (tr) * 1999-12-03 2004-01-21 Pfizer Products Inc. Anti-iltihabik / analjezik maddeler olarak heteroaril fenil pirazol bileşikleri.
WO2003084544A2 (en) * 2002-04-04 2003-10-16 Cv Therapeutics, Inc. Compounds dor increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis
AU2004228057A1 (en) 2003-04-03 2004-10-21 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
EP1618099A4 (en) * 2003-04-18 2008-07-16 Merck & Co Inc BIARYLSUBSTITUTED DIAZOLE, OXAZOLE AND IMIDAZOLE AS SODIUM CHANNEL BLOCKERS
WO2007138110A2 (en) * 2006-06-01 2007-12-06 Devgen N.V. Compounds that interact with ion channels, in particular with ion channels from the kv family
WO2008121861A2 (en) 2007-03-28 2008-10-09 Xenon Pharmaceuticals Inc. Pyrazole and pyrrole compounds useful in treating iron disorders
WO2009027393A2 (en) * 2007-08-27 2009-03-05 Basf Se Pyrazole compounds for controlling invertebrate pests
CA2720343A1 (en) * 2008-04-04 2009-10-08 Takeda Pharmaceutical Company Limited Heterocyclic derivative and use thereof
PT2275414E (pt) 2008-04-28 2015-09-09 Teijin Pharma Ltd Derivado de amida do ácido ciclopentacrílico
EP2651405A2 (en) * 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
WO2014066304A1 (en) * 2012-10-22 2014-05-01 Egenix, Inc. Compositions and methods for treating or preventing diseases or disorders associated with misregulated eif4e
US9926319B2 (en) 2014-03-27 2018-03-27 Merck Patent Gmbh Pyridyl piperidines
EP3656770A3 (en) 2015-04-24 2020-09-09 Syngenta Participations AG Pesticidally active polycyclic derivatives with sulfur substituted five-membered ring heterocycles
WO2016196644A1 (en) 2015-06-01 2016-12-08 Bantam Pharmaceutical, Llc Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto

Also Published As

Publication number Publication date
US20180311218A1 (en) 2018-11-01
BR112017025851A2 (pt) 2018-10-16
IL255898A (en) 2018-01-31
WO2016196644A1 (en) 2016-12-08
JP6707630B2 (ja) 2020-06-10
CN108349962A (zh) 2018-07-31
JP2018521119A (ja) 2018-08-02
CA3025492A1 (en) 2016-12-08
US20200261424A1 (en) 2020-08-20
US11602526B2 (en) 2023-03-14
US10537558B2 (en) 2020-01-21
EP3303332A1 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
MX2017015456A (es) Compuestos de pirazol y pirrol sustituidos y metodos para su uso por inhibición de iniciación de traducción y tratamiento de enfermedades y trastornos relacionados con ellos.
PH12019502436A1 (en) 6-6 fused bicyclic heteroaryl compounds and their use as lats inhibitors
PH12016502318A1 (en) Cyclic di-nucleotides as modulators of sting
PH12018500212A1 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
MY190408A (en) Compositions and methods for treating cns disorders
UA109220C2 (uk) Похідні (4-фенілімідазол-2-іл)етиламіну як модулятори натрієвих каналів
MX368504B (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
PH12016502352A1 (en) Pharmaceutical composition
MY169485A (en) Heterocyclic compounds suitable for the treatment of dyslipidemia
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
MX2020007985A (es) Inhibicion del canal ionico receptor de potencial transitorio a1.
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2022000083A (es) Inhibidores de monoacilglicerol lipasa (magl) heterociclicos.
PH12020551494A1 (en) Substituted imidazolidin-2-one derivatives as prmt5 inhibitors
RU2015112121A (ru) Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
MX2019007213A (es) Derivado de azaciclobutil triazol del grupo anular condensado, metodo de preparacion del mismo y uso del mismo en medicina.
PH12018500469A1 (en) Sulfonamide compounds as voltage-gated sodium channel modulators
MY193963A (en) Composition for treating joint diseases and kit containing same
MX2021011986A (es) Metodos de tratamiento de dolor neuropatico.